Arrowhead presents new pivotal Phase 3 data from PALISADE study of Plozasiran
PremiumThe FlyArrowhead presents new pivotal Phase 3 data from PALISADE study of Plozasiran
3M ago
Arrowhead to advance two RNAi-based obesity candidates into clinical studies
Premium
The Fly
Arrowhead to advance two RNAi-based obesity candidates into clinical studies
3M ago
Arrowhead price target lowered to $28 from $31 at Goldman Sachs
Premium
The Fly
Arrowhead price target lowered to $28 from $31 at Goldman Sachs
3M ago
Arrowhead price target lowered to $60 from $90 at H.C. Wainwright
PremiumThe FlyArrowhead price target lowered to $60 from $90 at H.C. Wainwright
5M ago
Arrowhead to advance plozasiran into Phase 3 cardiovascular outcomes trial
Premium
The Fly
Arrowhead to advance plozasiran into Phase 3 cardiovascular outcomes trial
5M ago
Arrowhead presents preclinical data on new ARO-INHBE
Premium
The Fly
Arrowhead presents preclinical data on new ARO-INHBE
5M ago
Arrowhead announces results from ARCHES-2 study
PremiumThe FlyArrowhead announces results from ARCHES-2 study
6M ago
Arrowhead presents new Phase 2 Data of plozasiran in hyperlipidemia
Premium
The Fly
Arrowhead presents new Phase 2 Data of plozasiran in hyperlipidemia
6M ago
Arrowhead announces new interim clinical data on ARO-RAGE
Premium
The Fly
Arrowhead announces new interim clinical data on ARO-RAGE
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100